RESEARKA

Several unresolved questions temper enthusiasm for grip strength longevity as a gerotherapeutic target. First, the mechanism–function gap: it remains unclear whether weak grip strength causes adverse outcomes through direct pathways such as sarcopenia-driven metabolic dysfunction, or whether it is simply a sentinel marker of global physiological reserve and accumulated damage. Second, dose–response relationships are poorly characterized; the relationship between handgrip strength and all-cause mortality appears to be modified by systemic inflammation level, with CRP thresholds of 3, 10, and 25 mg/L each yielding distinct risk profiles (TurBoned 2026), yet optimal therapeutic targets have not been defined. Third, the duration of any intervention needed to produce survival benefits is unknown; most exercise trials last weeks to months, while the epidemiological signal accumulates over years to decades. Fourth, there is the problem of competing risks—in older adults, mortality from non-musculoskeletal causes may overwhelm any benefit derived from improved grip strength alone. Evidence suggests that grip strength longevity may be most informative as part of composite frailty indices rather than as an isolated predictor, but this hypothesis requires formal testing.

Citation Support

• source_1 Jayanama 2022
• source_2 TurBoned 2026
• source_3 Karahan 2026
• source_4 Cui 2021
• source_5 Aksoy 2026